Condition

Hidradenitis Suppurativa (HS) clinical trials and research

• 23Clinical trials
• 25Countries

Newest Hidradenitis Suppurativa (HS) clinical trials

All recruiting trials (23)

• Soquelitinib in adults with hidradenitis suppurativa

  This study tests whether oral soquelitinib can help adults with moderate-to-severe hidradenitis suppurativa.

  Recruiting at 9 sites Phase 1 Corvus Pharmaceuticals, Inc. · West Lafayette, Indiana and 10 other locations · NCT07828860

• ORKA-002 versus placebo for moderate-to-severe hidradenitis suppurativa

  A study tests ORKA-002 against placebo in adults with moderate-to-severe hidradenitis suppurativa to see if it helps reduce symptoms.

  Recruiting at 25 sites Phase 2 Oruka Therapeutics, Inc. · Birmingham, Alabama and 24 other locations · NCT07783542

• SPY072 in adults with moderate to severe hidradenitis suppurativa

  This study tests whether SPY072 can help adults with moderate to severe hidradenitis suppurativa when added to their current care, compared with a placebo over 16 weeks.

  Recruiting at 7 sites Phase 2 Spyre Therapeutics, Inc. · Birmingham, Alabama and 33 other locations · NCT07766005

• Brain activity patterns in people with hidradenitis suppurativa and how treatments may relate to changes

  This study tests whether adults with hidradenitis suppurativa show different resting brain activity than healthy people and whether these brain patterns relate to symptoms like pain and mood, and whether they change after 3 months of standard biologic or small-molecule treatment.

  Recruiting Second Xiangya Hospital of Central South University · Changsha, Hunan · NCT07755670

• Roflumilast 0.3% Foam for Hidradenitis Suppurativa in Teens and Adults

  This study tests a topical roflumilast foam to see if it improves HS in adolescents and adults over 16 weeks.

  Recruiting Phase 2 Harrison Dermatology · Missouri City, Texas · NCT07689188

• Global health study on hidradenitis suppurativa

  This study tests how people with hidradenitis suppurativa access care and what treatments they receive across different health systems.

  Recruiting University of Zurich · Zurich · NCT07659769

• Secukinumab in Chinese adults with moderate to severe hidradenitis suppurativa

  This trial tests two dosing regimens of secukinumab to see if they can help Chinese adults with moderate to severe hidradenitis suppurativa.

  Recruiting at 10 sites Phase 4 Novartis · Guangzhou, Guangdong and 9 other locations · NCT07489573

• Radiotherapy for Moderate to Severe Hidradenitis Suppurativa in the Axilla

  This study tests whether high-dose radiotherapy to one armpit can reduce lesions and improve symptoms in adults with treatment-resistant hidradenitis suppurativa.

  Recruiting at 2 sites Thomas Jefferson University · Cherry Hill, New Jersey and 1 other locations · NCT07414550

• NAV-240 for adults with moderate-to-severe hidradenitis suppurativa

  This trial will test whether NAV-240 given by IV can reduce inflamed bumps and skin pain in adults with moderate-to-severe hidradenitis suppurativa compared with a placebo.

  Recruiting at 40 sites Phase 2 Navigator Medicines, Inc. · Phoenix, Arizona and 40 other locations · NCT07384975

• Pelashield PainGuard versus Restrata for healing after HS wide excision

  This research will test whether the Pelashield PainGuard dressing helps adults having wide excision for hidradenitis suppurativa heal faster and need less opioid pain medicine than the standard Restrata dressing.

  Recruiting Rutgers, The State University of New Jersey · Newark, New Jersey · NCT07316192

• Roflumilast 0.3% foam for hidradenitis suppurativa

  This trial tests whether applying 0.3% roflumilast foam once daily helps adults with mild-to-moderate hidradenitis suppurativa reduce painful bumps and inflammation over 16 weeks.

  Recruiting Phase 2 Beth Israel Deaconess Medical Center · Boston, Massachusetts · NCT07263230

• SCT650C for adults with moderate to severe hidradenitis suppurativa

  This trial will test whether subcutaneous injections of SCT650C help adults with moderate to severe hidradenitis suppurativa by reducing inflammatory lesions and symptoms.

  Recruiting Phase 2 Sinocelltech Ltd. · Samsun, Turkey · NCT07244510

• Povorcitinib for adolescents with moderate to severe hidradenitis suppurativa

  This trial tests the oral drug povorcitinib in adolescents aged 12–17 with moderate to severe hidradenitis suppurativa to see if it is safe, how the body handles it, and whether it reduces lesions over a 54-week treatment period.

  Recruiting at 28 sites Phase 2 Incyte Corporation · Birmingham, Alabama and 29 other locations · NCT07213973

• 1726-nm laser treatment for hidradenitis suppurativa (acne inversa)

  This will test whether a 1726‑nm diode laser can safely reduce painful inflammatory lesions in adults with mild-to-moderate (Hurley I–II) hidradenitis suppurativa by treating one side of the body while the other side receives a sham procedure.

  Recruiting Phase 1 Wynn Medical Center · Rosemead, California · NCT07155239

• Long-term safety follow-up after gene-modified regulatory T cell (Treg) therapy

  This study will see if any delayed side effects occur over 15 years in people who previously got a Sonoma Biotherapeutics gene-modified Treg treatment for conditions like rheumatoid arthritis or hidradenitis suppurativa.

  Recruiting at 7 sites Sonoma Biotherapeutics, Inc. · San Francisco, California and 9 other locations · NCT07123038

• Secukinumab for moderate-to-severe hidradenitis suppurativa

  This study tests whether secukinumab helps adults with moderate-to-severe hidradenitis suppurativa who have not improved with antibiotics, isotretinoin, or TNF inhibitors.

  Recruiting Peking Union Medical College · Beijing, Beijing Municipality · NCT07109765

• SKINERGY: deep biomarker profiling of immune-driven skin diseases in dermatology clinics

  This project will test whether detailed blood, tissue, imaging, and patient-reported biomarker profiles in adults with several immune-related skin conditions can find patterns that distinguish disease types and predict who responds to treatment.

  Recruiting Leiden University Medical Center · Nijmegen, Gelderland and 7 other locations · NCT07021495

• Testing QLS12010 Capsules in Healthy Adults

  This study is testing if QLS12010 Capsules are safe and how well they are tolerated by healthy adults while also looking at how food affects the way the body absorbs the drug.

  Recruiting Phase 1 Shanghai Qilu Pharmaceutical Research and Development Center LTD · Beijing · NCT06946641

• LT-002-158 tablets for hidradenitis suppurativa in Chinese adults

  This study tests LT-002-158 tablets in adults with moderate-to-severe hidradenitis suppurativa in China to see if they are safe and help reduce symptoms.

  Recruiting Phase 1/2 Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Beijing, Beijing Municipality · NCT06932003

• Evaluating secukinumab's effectiveness with surgery for hidradenitis suppurativa

  This study is testing if using secukinumab along with surgery can help people with moderate to severe hidradenitis suppurativa feel better and have fewer problems after surgery.

  Recruiting Peking Union Medical College · Nanjing, Jiangsu · NCT06926192

• Continuation of treatment with povorcitinib for previous trial participants

  This study lets people who have already benefited from the medication povorcitinib in a previous trial keep using it to see if it continues to help with their Hidradenitis Suppurativa.

  Recruiting at 247 sites Phase 3 Incyte Corporation · Birmingham, Alabama and 305 other locations · NCT06855498

• Short-term treatment satisfaction with Cosentyx for hidradenitis suppurativa in Saudi Arabia

  This will see if adults in Saudi Arabia with moderate-to-severe hidradenitis suppurativa who start Cosentyx are satisfied with its convenience, safety, and effectiveness after 24 weeks.

  Recruiting at 4 sites Novartis · Riyadh, SAU and 3 other locations · NCT06785779

• Topical cream EVO101 for treating mild to moderate hidradenitis suppurativa

  This study is testing a new cream called EVO101 to see if it can help adults with mild to moderate hidradenitis suppurativa feel better over twelve weeks.

  Recruiting Early Phase 1 Virginia Clinical Research, Inc. · Norfolk, Virginia · NCT06645821

Related topics

Quick answers

How many Hidradenitis Suppurativa (HS) clinical trials are recruiting right now?

23, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 25 countries. The most sites are in United States (13 trials), China (6 trials), Canada (5 trials), Netherlands (2 trials), Bulgaria (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 7, Phase 1: 3, Phase 4: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →